Vestibular Outcomes in Vestibular Schwannoma

Vertigo Symptoms, Balance and Vestibular Function in Patients With Vestibular Schwannoma

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03346889

Acronym

VOVS

Enrollment

155

Registered

2017-11-20

Start date

2017-04-23

Completion date

2025-12-31

Last updated

2024-10-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vestibular Schwannoma

Keywords

vestibular evoked myogenic potentials, head impulse testing, quality of life

Brief summary

Previous studies have shown that vertigo is the symptoms that mostly affect quality of life in patients with vestibular schwannoma. There is still limited knowledge as to why some patients with this disorder develop vertigo, while others with the same diagnosis do not. The purpose of this study is to measure symptom-related quality of life and to relate this to objective disease characteristics at baseline.

Detailed description

This is a longitudinal observational study with data collected at baseline and after treatment. Variables collected at baseline include age, sex, tumor size, location, type (cystic/solid), tumor side, symptom variables including Dizziness Handicap Inventory, Vertigo Symptom Scale Short Form, Haukeland Dizziness Questionnaire, Visual analog scale, Hospital Anxiety and Depression Scale, RAND-12, dynamic posturography, video-based head impulse test, bithermal caloric tests, ocular and cervical vestibular evoked myogenic potentials. Follow-up data after 1 year are the same patient-reported outcomes as at baseline.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* Patients living i Norway referred to Haukeland University Hospital due to newly diagnosed, untreated vestibular schwannoma

Exclusion criteria

* Inability to undergo test protocol due to physical or language barriers

Design outcomes

Primary

Measure	Time frame	Description
Dizziness Handicap Inventory (DHI)	Baseline and 1-year follow-up	25-item symptom score 0 - 100 points on dizziness handicap severity

Secondary

Measure	Time frame	Description
Vertigo Symptom Scale Short Form	Baseline and 1-year follow-up	15-item symptom score 0 - 60 points on vertigo symptom quality
Haukeland Dizziness Questionnaire (HDQ-10)	Baseline and 1-year follow-up	10-item symptom score 0 - 30 points on vertigo symptom severity
Vertigo Visual Analog Scale	Baseline and 1-year follow-up	100 mm visual analog scale on vertigo symptom severity
Hospital Anxiety and Depression Scale (HADS)	Baseline and 1-year follow-up	14-item anxiety and depression score 0 - 42 points
RAND-12	Baseline and 1-year follow-up	12-item health-related quality of life score

Countries

Norway

Outcome results